Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN has launched the QIAreach™ SARS-CoV-2 Antigen Test in the U.S., enabling rapid detection of SARS-CoV-2 antigens in 2-15 minutes for active infections. Developed with Ellume, the test can process over 30 samples per hour and offers digital results without subjective interpretation. An EUA application for symptomatic patients has been submitted, with plans for a POC claim later this year. The test addresses the need for scalable and accurate antigen testing as part of COVID-19 strategies, complementing PCR testing for higher throughput.
QIAGEN N.V. (NYSE: QGEN) announced a conference call set for October 28 to discuss third-quarter results for 2020, following the release of their financial report on October 27. The call will be at 14:00 Frankfurt time/13:00 London time/9:00 New York time, hosted by CEO Thierry Bernard and CFO Roland Sackers. Interested participants can join via phone or by accessing the webcast. QIAGEN specializes in Sample to Insight solutions, serving over 500,000 customers globally in Molecular Diagnostics and Life Sciences as of September 30, 2020.
QIAGEN N.V. (NYSE: QGEN) reported robust Q3 2020 results, with sales escalating by 26% to $483.8 million compared to $382.7 million in Q3 2019. Adjusted EPS soared 61% to $0.58. Encouraged by this performance, the company raised its 2020 outlook, forecasting 20% sales growth and adjusted EPS of $2.07-2.09. The significant sales increase is attributed to high demand for COVID-19 related products, alongside other portfolio areas. QIAGEN also expanded its COVID-19 testing capabilities and solidified its position in automated molecular testing through a recent acquisition.
QIAGEN N.V. (NYSE: QGEN) reported strong preliminary results for Q3 2020, with net sales rising 26% year-over-year to $481.3 million, surpassing prior growth forecasts. This growth is attributed to heightened demand for COVID-19 testing solutions, along with improved trends in non-COVID product sales. Adjusted EPS reached approximately $0.58, marking a 61% increase from $0.36 in Q3 2019. QIAGEN anticipates minimal currency impact on its results. Full Q3 results will be published on November 4, 2020, with a conference call scheduled for November 5.
QIAGEN (NYSE: QGEN) has announced a new approach to viral RNA epidemiology with its QIAprep Viral RNA UM Kit. This innovative kit simplifies PCR analysis for SARS-CoV-2 and other RNA viruses, allowing sample preparation in just two minutes. The streamlined process delivers results in under one hour, significantly faster than traditional methods that take about three hours. The kit can manage up to 2,600 samples in an eight-hour shift and minimizes plastic use while reducing reagent and labor costs. Initial studies show detection levels comparable to standard protocols.